CYP

AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients

CARLSBAD, Calif., Jan. 22 /PRNewswire/ -- AutoGenomics, a leader in providing automated molecular testing solutions announced today that its CYP450 2C19 assay was used in a study to demonstrate the value of genetic variants in dosing of the antiplatelet agent...

MULTAQ(R) (dronedarone) for Atrial Fibrillation or Atrial Flutter Now Available in the United States

... MULTAQ should not be given to patients who are or may become pregnant (Category X) or nursing. MULTAQ should not be coadministered with strong cyp 3A inhibitors or medicinal products that prolong the QT interval. In patients with new or worsening heart failure, the suspension or discontin...

FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter

...taq(R) should not be given to patients who are or may become pregnant (Category X) or nursing. Multaq(R) should not be coadministered with strong cyp 3A inhibitors or medicinal products that prolong the QT interval. In patients with new or worsening heart failure, the suspension or discontinua...

FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia

...ypovolemic hyponatremia, concomitant use of strong cyp 3A inhibitors, anuric patients ...Drugs Affecting Exposure to SAMSCA - cyp 3A Inhibitors - Do not use with strong inhibitors of cyp 3A; avoid concomitant use with moderate...

New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes

...c, black, Asian, and other racial groups. Drug Interactions Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of cyp isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a p-glycoprotein substrate, but does not inhibit p-g...

New Study Shows Efficacy of AROMASIN on Early Breast Cancer

... drug, or are taking estrogen-containing agents. Dose modification is recommended for patients who are receiving certain medications, including strong cyp 3A4 inducers such as rifampicin and phenytoin. In patients with early breast cancer, elevations in bilirubin, alkaline phosphatase, and creatini...

CYP in Medical Technology

Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.

Michael S. Singer, M.D., Ph.D. Contributing Editor Harvard Medical School The FDA approval of BiDil for heart failure in African American patients has underscored the concept that two patients can respond differently to the same medication. This concept holds true for a wide variety of ...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

...he active metabolite. Approximately 30 percent of Caucasians and 60 percent of Asians have reduced function in the CYP2C19 gene, which is part of the cyp system and encodes the enzymes that are responsible for converting prasugrel into its active form(2). In the substudy, researchers examined how v...

Clinical Update - Debio 025 in Hepatitis C

...rates the onset of action and enhances efficacy in the early stage of treatment. About Debio 025 Debio 025 is a synthetic first-in-class cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication ad...

Clinical Update - Debio 025 in Hepatitis C

...eatment which we hope to address," added Kamel Besseghir, CEO of Debiopharm S.A. About Debio 025 Debio 025 is a synthetic first-in-class cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication ad...

Clinical Update - Debio 025 in Hepatitis C

.... "This unique mechanism of action is the first alternative treatment to classic HCV therapies." Debio 025 Debio 025 is a synthetic first-in-class cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication ad...

Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment of HCV

...ohort with the highest dose in the protocol," said Kamel Besseghir, CEO of Debiopharm S.A. About Debio 025 Debio 025 is a synthetic first-in-class cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to cyclophilins, host cell proteins thought to confer a repli...

Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimer's Drug

...esired potentially toxicity or pharmacologically inactive metabolites. In addition, positive results were reported where SP-233 was shown to have no cyp inhibition potential for CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 suggesting that SP-233, is unlikely to cause, or alter the metabolism of co-admini...

Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection

...and potent activity in HCV replicon assays. The compound also displayed very good in vitro metabolic stability and did not significantly inhibit human cyp enzymes, suggesting a low potential for drug-drug interactions. Extending these in vitro findings, in vivo preclinical studies of ANA598 demonstrated ...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

...lack, Asian, and other racial groups. Drug Interactions In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of cyp isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a p-glycoprotein substrate, but does not inhibit p...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

...lack, Asian, and other racial groups. Drug Interactions In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of cyp isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a p-glycoprotein substrate, but does not inhibit p...

More>>

CYP in Biological News

NIH grants Phylonix Phase II SBIR to develop high-throughput in vivo zebrafish assays

...assessing drug effects on Cytochrome (CYP) P450s. cyp profiling, a critical step in drug development, is...tive Officer. "A rapid and robust whole zebrafish cyp assay, amenable to automation in multiwell plate f...e associated with inhibition and/or induction of a cyp enzyme, such as 3A4. Modification of...

Scientists unravel clue in cortisol production

... the nucleus to bind to the DNA, creating the gene cyp 17. What happens next is well understood; cyp 17, along with a battery of other enzymes, transfo...n't understood is how this protein binding creates cyp 17, or which proteins are important. So, graduate ...